About Avacta
Avacta is a publicly listed company based in Wetherby (United Kingdom) founded in 2003. Developer of therapeutics and diagnostics for the treatment of cancer. Avacta has completed 2 acquisitions, including CorisBio and Launch Diagnostics. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is AVACTA LIFE SCIENCES LIMITED.
Company details
Avacta was founded in 2003 and is based in Wetherby, United Kingdom. Operations focus on the biotechnology sector, where immunotherapies are developed by combining Affimer biotherapeutics with precision tumor-targeted chemotherapy. Diagnostics for cancer treatment are also advanced. The lead candidate, AVA6000, represents a tumor-targeted version of doxorubicin. Activities center on oncology solutions through these integrated platforms.
- Headquarters Wetherby, United Kingdom
- Stage Public
- SectorsHealthcare
- Email••••••••
- Website avacta.com
- Social LinkedIn X Facebook
- Legal Name Avacta Group Plc
- Annual Revenue$152.16 K (USD)as on Dec 31, 2025
- Net Profit-$51.68 M (USD)27.37as on Dec 31, 2025
- EBITDA-$39.01 M (USD)3.94as on Dec 31, 2025
- Latest Funding Round$21.47M (USD), Post-IPO
Oct 2025
- Investors
- Investments & AcquisitionsCorisBio
& 1 more
Funding Insights of Avacta
- Total Rounds 13
- Last Round Post-IPO — $21.47M
- First Round $3.04M
(Jan 2011)
- Investors Count 1
Latest 10 of 13 funding rounds of Avacta with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2025 | $21.47M | Post-IPO | – | – | – |
| Aug 2025 | $4.39M | Post-IPO | – | – | – |
| Feb 2024 | $32.53M | Post-IPO | – | – | – |
| Nov 2022 | $73.13M | Post-IPO | – | – | – |
| Apr 2020 | $4.64M | Post-IPO | – | – | – |
| Jul 2018 | $13.55M | Post-IPO | – | – | – |
| Aug 2016 | $4.94M | Grant | – | – | |
| Feb 2016 | Grant | – | – | – | |
| Jul 2015 | $34.17M | Post-IPO | – | – | – |
| Feb 2015 | $5M | Post-IPO | – | – | – |
1 investors in total: 1 institutional.
Investors in Avacta
Avacta has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Medical Research Council.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Medical research is conducted to advance human health improvements. | 1913 | mrc.ac.uk | Swindon, United Kingdom |
Investor details for Avacta
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Avacta
29 people are tracked at Avacta (7 in leadership, 8 in board & advisors, 14 in team).
| Name | Role | Group |
|---|---|---|
Karen Harrison | COO, Therapeautics | Leadership |
Jose Saro | Chief Medical Officer | Leadership |
Michelle Morrow | Chief Scientific Officer | Leadership |
Brian Hahn | Chief Financial Officer | Leadership |
Francis W. | VP Chemistry | Leadership |
David Jones | Vp, Head Of Biology | Leadership |
Christina Coughlin | Chief Executive Officer | Leadership |
Eliot Forster | Non Executive Chairman | Board & advisors |
Mike Owen | Senior Independent Director & Scientific Advisory Board Chairman | Board & advisors |
Sam Williams | Non Executive Director | Board & advisors |
Adrian Hayday | Scientific Advisory Board Member | Board & advisors |
Terence H Rabbitts | Scientific Advisory Board Member | Board & advisors |
Paul Moss | Scientific Advisory Board Member | Board & advisors |
Gerard Evan | Scientific Advisory Board Member | Board & advisors |
Trevor Nicholls | Non Executive Director | Board & advisors |
Folake Orafidiya | Senior Scientist | Team |
Emma Wright | Group In-House Counsel | Team |
Victoria Juskaite | Principal Scientist | Team |
Sophie Brown | Senior Scientist | Team |
Helen Butler | Senior Assay Development Scientist, IVD | Team |
9 more people are available in the full profile.
Complete people profiles for Avacta
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Avacta
Avacta is a publicly listed company on the LSE with ticker symbol AVCT in UK, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date08 Aug 2006
- Listed onLSE: AVCT
- Listed entityAvacta Group PLC
- Exchange sectorCommercial services
- ISINGB00BYYW9G87
- Share price62.99 GBX (-0.8% on the day) · 2026-10-14
- Market capitalisation309,109,539.00 GBX
- EPS (diluted, trailing year)-0.09 GBX
- Volume (last session)629,579
Financials of Avacta
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 113,000 GBP | -38.4M GBP | -29.0M GBP |
| 2024 | 113,000 GBP | -52.8M GBP | -30.2M GBP |
| 2023 | 2.9M GBP | -33.3M GBP | -20.7M GBP |
| 2022 | 9.7M GBP | -36.9M GBP | -22.5M GBP |
| 2021 | 2.9M GBP | -26.3M GBP | -26.7M GBP |
Detailed financial statements for Avacta
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avacta
Avacta has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include CorisBio and Launch Diagnostics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Rapid diagnostic tests for infectious diseases are developed and commercialized. | corisbio.com | Gembloux, Belgium | 1996 | Jun 2023 | $9.17M | |
High-quality diagnostic reagents and instruments are supplied to healthcare providers. | launchdiagnostics.com | Longfield, United Kingdom | 1990 | Oct 2022 | $27.15M |
Complete acquisition details for Avacta
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Avacta
6 dated milestones of Avacta across 22 years, from founding to its latest funding, stage changes and deals.
- Founded Avacta is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $3.0M.
- Acquisition Acquires Launch Diagnostics.
- Acquisition Acquires CorisBio.
- Funding Latest funding round, Post-IPO, of $21.5M.
Web traffic of Avacta
The website of Avacta (avacta.com) receives about 6K visits a month.
- Monthly visits6K
▼ 4% vs previous month
Websites whose visitors overlap most with Avacta. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| leco.com | 100% | 43.6K | #720,718 | View details | |
avactalifesciences.com | avactalifesciences.com | 52% | – |
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as Avacta (Life Sciences Platforms & Tools) in United Kingdom, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | |||
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Avacta
Complete news archive for Avacta
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avacta
Avacta was founded in 2003 and raised its 1st funding round 8 years after it was founded.
Avacta is headquartered in Wetherby, United Kingdom. It is registered at Wetherby, West Yorkshire, United Kingdom.
Annual revenue of Avacta is $152.16K as on Dec 31, 2025.
Avacta was founded in 2003 and is based in Wetherby, United Kingdom. Operations focus on the biotechnology sector, where immunotherapies are developed by combining Affimer biotherapeutics with precision tumor-targeted chemotherapy. Diagnostics for cancer treatment are also advanced. The lead candidate, AVA6000, represents a tumor-targeted version of doxorubicin. Activities center on oncology solutions through these integrated platforms.
Yes, Avacta is publicly traded on LSE under the ticker symbol AVCT.
Avacta has made 2 acquisitions, including CorisBio, and Launch Diagnostics.
Avacta has 1 investor. Key investors include Medical Research Council.
Avacta operates through Avacta Life Sciences Limited.